Lexaria's DehydraTECH Technology Shows Enhanced Brain Delivery of GLP-1 Drug in Preclinical Study
TL;DR
Lexaria's DehydraTECH technology delivers semaglutide more effectively to the brain than Rybelsus, potentially offering superior safety and efficacy advantages in GLP-1 drug markets.
Lexaria's DehydraTECH processing enhances brain biodistribution of semaglutide through improved delivery across the blood-brain barrier, as evidenced by fluorescent imaging in rodent studies.
Enhanced brain delivery of GLP-1 drugs could reduce side effects like nausea while improving weight management, making treatments safer and more effective for patients worldwide.
Lexaria's technology shows semaglutide reaching key brain regions at higher levels than conventional formulations, potentially explaining improved drug performance in human trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Lexaria Bioscience Corp. has announced successful results from a preclinical study showing that its DehydraTECH technology enhances brain biodistribution of the GLP-1 drug semaglutide compared to conventional formulations. The study found that DehydraTECH-processed semaglutide achieved higher fluorescent signal intensity in brain tissue across all tested doses, with the 5mg DehydraTECH composition outperforming the 15mg Rybelsus equivalent composition in brain delivery.
The research involved detailed examination of specific brain regions known to interact with semaglutide, including the brainstem, paraventricular nucleus of the hypothalamus, and circumventricular organs. All three DehydraTECH doses tested displayed fluorescence above control groups, while only the highest dosage of the Rybelsus equivalent composition surpassed control levels. This enhanced brain delivery could be significant because GLP-1 drug performance increasingly depends on brain neurochemistry involvement for regulating body weight through GLP-1 receptor activation.
John Docherty, Lexaria President and CSO, stated that the company has repeatedly evidenced higher brain levels with DehydraTECH-processed active ingredients in previous rodent studies that demonstrated superior safety and efficacy over controls. The current findings may help explain the performance benefits observed in related human clinical testing to date. The study utilized fluorescently tagged semaglutide with cyanine 7 fluorophore for visualization, allowing for deeper tissue penetration and minimal background signal during emission measurements.
The implications of this research are substantial for the development of next-generation GLP-1 therapies. Enhanced brain biodistribution could potentially lead to improved appetite suppression without causing nausea, which remains one of the most common side effects of current GLP-1 treatments. The study suggests that Lexaria's DehydraTECH technology may enable unique delivery and distribution enhancements in brain tissue, possibly supporting improved pharmacodynamic performance for diabetes and weight management medications.
While these results are from an early-stage preclinical pilot study involving 25 Sprague Dawley rats and qualitative analysis without statistical interpretation, Lexaria considers them highly encouraging for additional research and potential industry partnerships. The company aims to contribute to developing safer and more effective GLP-1 drugs on the market through its patented drug delivery platform technology. For more information about the company's technology, visit https://www.lexariabioscience.com.
Curated from NewMediaWire
